Wells Fargo & Company Nuvectis Pharma, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$6.69 - $11.0 $1,993 - $3,278	298 Added 15.67%	2,200 $18,000
Q4 2023 Feb 09, 2024	BUY	$7.85 - $11.78 $3,430 - $5,147	437 Added 29.83%	1,902 $15,000
Q3 2023 Nov 13, 2023	SELL	$12.89 - $16.29 $17,788 - $22,480	-1,380 Reduced 48.51%	1,465 $18,000
Q2 2023 Aug 15, 2023	BUY	$12.62 - $18.4 $35,588 - $51,887	2,820 Added 11280.0%	2,845 $45,000
Q4 2022 Feb 13, 2023	BUY	$6.7 - $7.74 $6 - $7	1 Added 4.17%	25 $0
Q3 2022 Nov 14, 2022	BUY	$7.09 - $13.0 $21 - $39	3 Added 14.29%	24 $0
Q2 2022 Aug 12, 2022	BUY	$7.02 - $20.44 $7 - $20	1 Added 5.0%	21 $0
Q1 2022 May 16, 2022	BUY	$3.25 - $9.1 $65 - $182	20 New	20 $0

1.65M

Ticker NVCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,642,500
Market Cap $74.2M
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.